Roche tops cancer reputation rankings as AstraZeneca climbs back
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back…
British Business Headlines: GSK Investment, Burberry Stake, AstraZeneca Challenges, Glencore Allegations, Football Deal Talks
In a significant economic development, pharma giant GSK announced plans to establish a global research and development headquarters…
Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?
Novartis’ shift toward high-innovation pharmaceuticals has made regulatory milestones, late-stage trial results, and new product rollouts top priorities…
UBS stays positive on AstraZeneca ahead of second-quarter results
UBS stays positive on AstraZeneca ahead of second-quarter results Proactive uses images sourced from Shutterstock UBS expects AstraZeneca…
UBS stays positive on AstraZeneca ahead of second-quarter results
UBS stays positive on AstraZeneca ahead of second-quarter results Proactive uses images sourced from Shutterstock UBS expects AstraZeneca…
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety…
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark,…
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do Proactive…
Top pharmaceutical companies for innovation: Roche, AbbVie, Novartis, and more
The 2020 Pharmaceutical Invention and Innovation Indices, compiled by IDEA Pharma, were generated prior to the unfolding COVID-19…
Novartis advances actinium-based cancer drug after promising trial data
Novartis (SWX: NOVN) reported encouraging early clinical results on Sunday for an experimental prostate cancer treatment that uses…
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do Proactive…
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against…